Jun 29, 2021 5:30 am EDT Achieve Announces Completion of Target Enrollment of 750 Subjects in Phase 3 ORCA-2 Smoking Cessation Trial of Cytisinicline
Jun 3, 2021 5:30 am EDT Achieve Announces Allowance of U.S. Patents for Dosing and Administration of Cytisinicline for the Treatment and Prevention of Addiction
Jun 2, 2021 5:30 am EDT Achieve Life Sciences to Present at LD Micro Invitational XI Virtual Conference
May 27, 2021 4:05 pm EDT Achieve Life Sciences Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares
May 25, 2021 8:30 am EDT Achieve Life Sciences Announces Pricing of $20 Million Underwritten Public Offering
May 13, 2021 4:05 pm EDT Achieve Reports Financial Results for First Quarter 2021 and Provides Corporate Update
May 4, 2021 5:30 am EDT Achieve Life Sciences to Announce First Quarter 2021 Financial Results and Host Conference Call and Webcast on May 13, 2021
Apr 22, 2021 5:30 am EDT Achieve Life Sciences, Inc. to Host Virtual Non-Deal Roadshow on Tuesday, April 27, 2021
Apr 14, 2021 5:30 am EDT Achieve Announces Publication of the ORCA-1 Phase 2b Clinical Trial of Cytisinicline in Adult Smokers in Nicotine and Tobacco Research